CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ultrasound-Driven Nanomachine for Enhanced Sonodynamic Therapy of Non-Small-Cell Lung Cancer.
Ultrasound-Driven Nanomachine for Enhanced Sonodynamic Therapy of Non-Small-Cell Lung Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
非小细胞肺癌(NSCLC)是最常见的肺癌类型,亟需开发新型疗法。声动力疗法具有优异的组织穿透性和对健康组织损伤极小的特点,使其在癌症治疗中极具前景。SDT的疗效受到复杂的免疫微环境和肿瘤治疗耐药性的限制。本研究开发了靶向纳米颗粒,利用超声聚焦治疗NSCLC。该杂合靶向纳米颗粒以金纳米颗粒为基础成分,外部修饰工程化巨噬细胞外泌体和适配体S11e以特异性靶向NSCLC。超声可通过靶向纳米颗粒破坏溶酶体,从而有效消除NSCLC细胞中的肿瘤。同时,碎片化的肿瘤抗原可有效激活树突状细胞以招募T细胞。该方法在抑制NSCLC发展方面具有显著疗效,并展现出治疗应用的潜力。
Non-small-cell lung cancer (NSCLC) is the most prevalent type of lung cancer, and there is an urgent need for developing novel therapies. Sonodynamic therapy exhibits exceptional tissue penetration and minimal harm to healthy tissue, making it extremely promising for cancer treatment. The efficacy of SDT is limited by the intricate immunological microenvironment and the resistance to tumor treatment.
This study developed targeted nanoparticles that use ultrasound to concentrate on treating NSCLC. The hybrid targeted nanoparticles utilize gold nanoparticles as their fundamental component, with the outside modified with engineered macrophage exosomes and the aptamer S11e to specifically target NSCLC.
Ultrasound could effectively eliminate tumors in NSCLC cells by destroying lysosomes via targeted nanoparticles. Simultaneously, fragmented tumor antigens could effectively activate dendritic cell cells to recruit T cells. This method has significant efficacy in suppressing the development of NSCLC and exhibits potential for therapeutic application.
MEMBER ACCOUNT
登录成功会直接打开下一页。